Sugi Predict

Sugi Predict / Compounds / SCHEMBL799201

SCHEMBL799201

SCHEMBL799201

CN1CCN(C(=O)CO)CC1

nearest known ligand 0.54

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ HTR1A P08908 1/20 0.48
▸ POLB P06746 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ MAPT P10636 1/20 0.44
▸ PHGDH O43175 1/20 0.44
▸ MGLL Q99685 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ KMT2A Q03164 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8642977 0.87 — —
SCHEMBL10972781 0.87 ALDH1A1 (0.50) TDP1POLBL3MBTL1GAAKMT2A
SCHEMBL6044018 0.81 TDP1 (0.50) TDP1CYP1A2HTR1APOLBL3MBTL1
SCHEMBL13655796 0.81 GNAI3 (0.58) TDP1CYP1A2
SCHEMBL1385227 0.80 TDP1 (0.54) TDP1CYP1A2HTR1APOLBL3MBTL1
SCHEMBL6042558 0.80 CYP1A2 (0.54) TDP1CYP1A2MAPTKMT2AHTT
SCHEMBL802314 0.80 CYP1A2 (0.54) TDP1CYP1A2HTR1AMAPTPHGDH
SCHEMBL508614 0.79 GAA (0.51) TDP1CYP1A2HTR1APOLBL3MBTL1
SCHEMBL7469848 0.78 TDP1 (0.52) TDP1CYP1A2HTR1AMAPTPHGDH
SCHEMBL1447148 0.78 TDP1 (0.52) TDP1CYP1A2HTR1APOLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4838121-B2 — — 2011-12-14 — — JP claimed
EP-1641764-B1 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS NOVARTIS AG (CH) 2011-07-27 — — EP claimed
EP-2298743-A1 5-membered heterocycle-based P38 kinase inhibitors Novartis AG (CH) 2011-03-23 — — EP claimed
JP-2007521278-A — — 2007-08-02 — — JP claimed
EP-1641764-A1 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS Novartis AG (CH) 2006-04-05 — — EP claimed
US-20050049288-A1 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS MEREO BIOPHARMA 1 LIMINTED (GB) 2005-03-03 — — US claimed
WO-2005009973-A1 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS NOVARTIS AG (CH) 2005-02-03 — — WO claimed
US-12479826-B2 Pyridazinyl amino derivatives as ALK5 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-11-25 — — US disclosed
US-12247013-B2 Indane derivatives for use in the treatment of bacterial infection ANTABIO SAS (FR) 2025-03-11 — — US disclosed
EP-4182308-B1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARM SPA (IT) 2024-09-04 — — EP disclosed
CN-113166084-B Indane derivatives for the treatment of bacterial infections 安塔比奥公司 2024-06-04 — — CN disclosed
US-20240016941-A1 COMBINATION THERAPY ANTABIO SAS (FR) 2024-01-18 — — US disclosed
US-20240016941-A1 COMBINATION THERAPY ANTABIO SAS (FR) 2024-01-18 — — US disclosed
WO-2007025284-A1 TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2007-03-01 — — WO disclosed
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives THOMAS RICHARD C 2007-01-18 — — US disclosed
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives THOMAS RICHARD C 2007-01-18 — — US disclosed
US-20060089355-A1 Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides ELAN PHARMACEUTICALS, INC. 2006-04-27 — — US disclosed
US-5641778-A EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1997-06-24 — — US disclosed
EP-0716077-A1 Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors CIBA-GEIGY AG (CH) 1996-06-12 — — EP disclosed
US-4898871-A Pyrrole derivatives and pharmaceutical compositions which contain them as hypnotics and anticonvulsants RHONE-POULENC SANTE (FR) 1990-02-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049288-A1 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS MAPK1, MAP3K1, MAP3K8 TDP1 1097/4885CYP1A2 1122/4885HTR1A 2661/4885
US-20240016941-A1 COMBINATION THERAPY CFTR, ABCB11, SLC26A4 TDP1 4557/4885CYP1A2 1551/4885HTR1A 3027/4885
US-20060089355-A1 Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides APP, BACE1, BACE2 TDP1 381/4885CYP1A2 1848/4885HTR1A 1424/4885
US-12479826-B2 Pyridazinyl amino derivatives as ALK5 inhibitors ALK, TGFBR1, ACVR1 TDP1 2987/4885CYP1A2 3069/4885HTR1A 2440/4885
US-12247013-B2 Indane derivatives for use in the treatment of bacterial infection ELANE, ARG1, INSRR TDP1 4126/4885CYP1A2 507/4885HTR1A 3758/4885
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 TDP1 4622/4885CYP1A2 244/4885HTR1A 3363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.